Sesen Bio, Inc (SESN) Likely to See Priority Review for Vicineum, Canaccord Genuity Considers a "Must-Own for 2021"
Tweet Send to a Friend
Canaccord Genuity analyst John Newman reiterated a Buy rating and $5.00 price target on Sesen Bio, Inc (NASDAQ: SESN) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
